ProteqFlu

Country: European Union

Language: Icelandic

Source: EMA (European Medicines Agency)

Active ingredient:

Vcp 2242 veira / Vcp1529 veira / Vcp1533 veira / vCP3011 veira

Available from:

Boehringer Ingelheim Vetmedica GmbH

ATC code:

QI05AD02

INN (International Name):

Equine influenza vaccine (live recombinant)

Therapeutic group:

Hestar

Therapeutic area:

Ónæmislyf, Lifandi veiru bóluefni hrossum inflúensu veira

Therapeutic indications:

Virkt ónæmisaðgerðir hrossa fjórum mánaða eða eldri gegn hestum inflúensu til að draga úr klínískum einkennum og útskilnaði vírusa eftir sýkingu.

Product summary:

Revision: 14

Authorization status:

Leyfilegt

Authorization date:

2003-03-06

Patient Information leaflet

                                13
B. FYLGISEÐILL
14
FYLGISEÐILL
PROTEQFLU STUNGULYF, DREIFA HANDA HESTUM
1.
HEITI OG HEIMILISFANG MARKAÐSLEYFISHAFA OG ÞESS FRAMLEIÐANDA
SEM BER ÁBYRGÐ Á LOKASAMÞYKKT, EF ANNAR
Markaðsleyfishafi:
Boehringer Ingelheim Vetmedica GmbH
55216 Ingelheim/Rhein
ÞÝSKALAND
Framleiðandi sem ber ábyrgð á lokasamþykkt:
Boehringer Ingelheim Animal Health France SCS
Laboratoire Porte des Alpes
Rue de l'Aviation
69800 Saint Priest
FRAKKLAND
2.
HEITI DÝRALYFS
ProteqFlu, stungulyf, dreifa handa hestum.
3.
VIRK(T) INNIHALDSEFNI OG ÖNNUR INNIHALDSEFNI
Hver 1 ml skammtur inniheldur:
VIRK INNIHALDSEFNI:
Influenza A/eq/Ohio/03 [H
3
N
8
] raðbrigða canarypox veira (vCP2242) .................... ≥ 5,3
log10 FAID
50
*
Influenza A/eq/Richmond/1/07 [H
3
N
8
] raðbrigða canarypox veira (vCP3011)......... ≥ 5,3 log10 FAID
50
*
*vCP innihald og hlutfall vCP mælt með alþjóðlegu FAID
50
(Fluorescent assay infectious dose 50 %)
og qPCR.
ÓNÆMISGLÆÐIR:
Carbomer
...........................................................................................................................................
4 mg.
4.
ÁBENDING(AR)
Virk ónæming hjá hestum, fjögurra mánaða og eldri, gegn
hestainflúensu, til þess að draga úr
klínískum einkennum og útskiljun veirunnar eftir að sýking hefur
átt sér stað.
Upphaf ónæmis: 14 dögum eftir grunnbólusetningu (primary
vaccination course).
Tímalengd ónæmis sem bólusetningaráætlun veitir: 5 mánuðir
eftir grunnbólusetningu og 1 ár eftir
þriðju bólusetningu.
5.
FRÁBENDINGAR
Engar.
15
6.
AUKAVERKANIR
Tímabundinn þroti, sem yfirleitt gengur til baka innan 4 daga, getur
komið fram á stungustað. Í mjög
sjaldgæfum tilvikum getur þrotinn orðið allt að 15-20 cm í
þvermáli og varað í allt að 2-3 vikur, sem
gæti krafist meðferðar við einkennum.
Í mjög sjaldgæfum tilvikum geta verkir, staðbundinn hiti og
stífleiki í vöðvum komið fram.
Örsjaldan má sjá kýlamyndun.
Væg hækkun getur orðið á líkamshita (mest 1,5 °C) í einn
s
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
VIÐAUKI I
SAMANTEKT Á EIGINLEIKUM LYFS
2
1.
HEITI DÝRALYFS
ProteqFlu, stungulyf, dreifa handa hestum.
2.
INNIHALDSLÝSING
Hver 1 ml skammtur inniheldur:
VIRK INNIHALDSEFNI:
Influenza A/eq/Ohio/03 [H
3
N
8
] raðbrigða canarypox veira (vCP2242) .................... ≥ 5,3
log10 FAID
50
*
Influenza A/eq/Richmond/1/07 [H
3
N
8
] raðbrigða canarypox veira (vCP3011)......... ≥ 5,3 log10 FAID
50
*
* vCP innihald og hlutfall vCP mælt með alþjóðlegu FAID
50
(Fluorescent assay infectious dose 50 %)
og qPCR.
ÓNÆMISGLÆÐIR:
Carbomer
............................................................................................................................................
4 mg
Sjá lista yfir öll hjálparefni í kafla 6.1.
3.
LYFJAFORM
Stungulyf, dreifa.
4.
KLÍNÍSKAR UPPLÝSINGAR
4.1
DÝRATEGUND(IR)
Hestar.
4.2
ÁBENDINGAR FYRIR TILGREINDAR DÝRATEGUNDIR
Virk ónæming hjá hestum, fjögurra mánaða og eldri, gegn
hestainflúensu, til þess að draga úr
klínískum einkennum og útskiljun veirunnar eftir að sýking hefur
átt sér stað.
Upphaf ónæmis: 14 dögum eftir grunnbólusetningu (primary
vaccination course).
Tímalengd ónæmis sem bólusetningaráætlun veitir: 5 mánuðir
eftir grunnbólusetningu og 1 ár eftir
þriðju bólusetningu.
4.3
FRÁBENDINGAR
Engar.
4.4
SÉRSTÖK VARNAÐARORÐ
Engin.
4.5
SÉRSTAKAR VARÚÐARREGLUR VIÐ NOTKUN
Sérstakar varúðarreglur við notkun hjá dýrum
Aðeins skal bólusetja heilbrigð dýr.
3
Sérstakar varúðarreglur fyrir þann sem gefur dýrinu lyfið
Ef sá sem annast lyfjagjöf sprautar sig með dýralyfinu fyrir
slysni, skal tafarlaust leita til læknis og
hafa meðferðis fylgiseðil eða umbúðir dýralyfsins.
4.6
AUKAVERKANIR (TÍÐNI OG ALVARLEIKI)
Tímabundinn þroti, sem yfirleitt gengur til baka innan 4 daga, getur
komið fram á stungustað. Í mjög
sjaldgæfum tilvikum getur þrotinn orðið allt að 15-20 cm í
þvermáli og varað í allt að 2-3 vikur, sem
gæti krafist meðferðar við einkennum.
Í mjög sjaldgæfum tilvikum geta 
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 23-11-2020
Public Assessment Report Public Assessment Report Bulgarian 17-10-2014
Patient Information leaflet Patient Information leaflet Spanish 23-11-2020
Public Assessment Report Public Assessment Report Spanish 17-10-2014
Patient Information leaflet Patient Information leaflet Czech 23-11-2020
Public Assessment Report Public Assessment Report Czech 17-10-2014
Patient Information leaflet Patient Information leaflet Danish 23-11-2020
Public Assessment Report Public Assessment Report Danish 17-10-2014
Patient Information leaflet Patient Information leaflet German 23-11-2020
Public Assessment Report Public Assessment Report German 17-10-2014
Patient Information leaflet Patient Information leaflet Estonian 23-11-2020
Public Assessment Report Public Assessment Report Estonian 17-10-2014
Patient Information leaflet Patient Information leaflet Greek 23-11-2020
Public Assessment Report Public Assessment Report Greek 17-10-2014
Patient Information leaflet Patient Information leaflet English 23-11-2020
Public Assessment Report Public Assessment Report English 17-10-2014
Patient Information leaflet Patient Information leaflet French 23-11-2020
Public Assessment Report Public Assessment Report French 17-10-2014
Patient Information leaflet Patient Information leaflet Italian 23-11-2020
Public Assessment Report Public Assessment Report Italian 17-10-2014
Patient Information leaflet Patient Information leaflet Latvian 23-11-2020
Public Assessment Report Public Assessment Report Latvian 17-10-2014
Patient Information leaflet Patient Information leaflet Lithuanian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 23-11-2020
Public Assessment Report Public Assessment Report Lithuanian 17-10-2014
Patient Information leaflet Patient Information leaflet Hungarian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 23-11-2020
Public Assessment Report Public Assessment Report Hungarian 17-10-2014
Patient Information leaflet Patient Information leaflet Maltese 23-11-2020
Public Assessment Report Public Assessment Report Maltese 17-10-2014
Patient Information leaflet Patient Information leaflet Dutch 23-11-2020
Public Assessment Report Public Assessment Report Dutch 17-10-2014
Patient Information leaflet Patient Information leaflet Polish 23-11-2020
Public Assessment Report Public Assessment Report Polish 17-10-2014
Patient Information leaflet Patient Information leaflet Portuguese 23-11-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 23-11-2020
Public Assessment Report Public Assessment Report Portuguese 17-10-2014
Patient Information leaflet Patient Information leaflet Romanian 23-11-2020
Public Assessment Report Public Assessment Report Romanian 17-10-2014
Patient Information leaflet Patient Information leaflet Slovak 23-11-2020
Public Assessment Report Public Assessment Report Slovak 17-10-2014
Patient Information leaflet Patient Information leaflet Slovenian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 23-11-2020
Public Assessment Report Public Assessment Report Slovenian 17-10-2014
Patient Information leaflet Patient Information leaflet Finnish 23-11-2020
Public Assessment Report Public Assessment Report Finnish 17-10-2014
Patient Information leaflet Patient Information leaflet Swedish 23-11-2020
Public Assessment Report Public Assessment Report Swedish 17-10-2014
Patient Information leaflet Patient Information leaflet Norwegian 23-11-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 23-11-2020
Patient Information leaflet Patient Information leaflet Croatian 23-11-2020
Public Assessment Report Public Assessment Report Croatian 17-10-2014

View documents history